Avidity Biosciences Statistics
Share Statistics
Avidity Biosciences has 120.54M
shares outstanding. The number of shares has increased by 25.7%
in one year.
| Shares Outstanding | 120.54M |
| Shares Change (YoY) | 25.7% |
| Shares Change (QoQ) | 0.76% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 767 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 15.58M, so 12.93% of the outstanding
shares have been sold short.
| Short Interest | 15.58M |
| Short % of Shares Out | 12.93% |
| Short % of Float | 13.05% |
| Short Ratio (days to cover) | 13.28 |
Valuation Ratios
The PE ratio is -10.07 and the forward
PE ratio is -6.92.
Avidity Biosciences's PEG ratio is
14.65.
| PE Ratio | -10.07 |
| Forward PE | -6.92 |
| PS Ratio | 297.77 |
| Forward PS | 3.1 |
| PB Ratio | 2.28 |
| P/FCF Ratio | -10.54 |
| PEG Ratio | 14.65 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Avidity Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.73,
with a Debt / Equity ratio of 0.
| Current Ratio | 15.73 |
| Quick Ratio | 15.73 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $27,869.57 |
| Profits Per Employee | $-824,301.79 |
| Employee Count | 391 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 15.2% in the
last 52 weeks. The beta is 0.99, so Avidity Biosciences's
price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | 15.2% |
| 50-Day Moving Average | 29.48 |
| 200-Day Moving Average | 36.36 |
| Relative Strength Index (RSI) | 52.18 |
| Average Volume (20 Days) | 1,525,691 |
Income Statement
In the last 12 months, Avidity Biosciences had revenue of 10.9M
and earned -322.3M
in profits. Earnings per share was -2.89.
| Revenue | 10.9M |
| Gross Profit | 8.12M |
| Operating Income | -378.94M |
| Net Income | -322.3M |
| EBITDA | -378.94M |
| EBIT | -378.94M |
| Earnings Per Share (EPS) | -2.89 |
Full Income StatementBalance Sheet
The company has 219.87M in cash and 6.8M in
debt, giving a net cash position of 213.07M.
| Cash & Cash Equivalents | 219.87M |
| Total Debt | 6.8M |
| Net Cash | 213.07M |
| Retained Earnings | -893.07M |
| Total Assets | 1.46B |
| Working Capital | 1.35B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -300.87M
and capital expenditures -7.07M, giving a free cash flow of -307.94M.
| Operating Cash Flow | -300.87M |
| Capital Expenditures | -7.07M |
| Free Cash Flow | -307.94M |
| FCF Per Share | -2.76 |
Full Cash Flow StatementMargins
Gross margin is 74.53%, with operating and profit margins of -3477.43% and -2957.71%.
| Gross Margin | 74.53% |
| Operating Margin | -3477.43% |
| Pretax Margin | -2957.71% |
| Profit Margin | -2957.71% |
| EBITDA Margin | -3477.43% |
| EBIT Margin | -3477.43% |
| FCF Margin | -2825.88% |
